Phaseline

Companies › Shanghai Virogin Biotech

Shanghai Virogin Biotech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VG2062
Recombinant oncolytic HSV-1 expressing human IL-12 and IL-15
–Phase 1Advanced Malignant Solid TumorMay 2027
VG2025
Recombinant human IL-12/IL-15 dual-regulated oncolytic HSV-1
–Phase 1Advanced Malignant Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05477849VG2025Phase 1Advanced Malignant Solid TumorOncologyOct 2025
NCT07262164VG2062Phase 1Advanced Malignant Solid TumorOncologyMay 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.